From Nusinersen to Inclisiran, oligonucleotide APIs are rapidly reshaping modern drug development. Explore the role of oligonucleotide CDMOs in enabling analytical innovation and scalable, compliant manufacturing across the RNA therapeutic frontier.
Sheri Ambriz, MBA took the stage at TIDES USA 2025 in San Diego, CA, to share insights on green approaches to peptide and peptide–oligonucleotide conjugate manufacturing.
